Benslimane Nesrine, Loret Camille, Chazelas Pauline, Favreau Frédéric, Faye Pierre-Antoine, Lejeune Fabrice, Lia Anne-Sophie
GEIST Institute, University of Limoges, NeurIT UR 20218, F-87000 Limoges, France.
Centre Hospitalo-Universitaire (CHU) Limoges, Department of Biochemistry and Molecular Genetics, F-87000 Limoges, France.
Pharmaceuticals (Basel). 2024 Feb 28;17(3):314. doi: 10.3390/ph17030314.
Nonsense mutations that generate a premature termination codon (PTC) can induce both the accelerated degradation of mutated mRNA compared with the wild type version of the mRNA or the production of a truncated protein. One of the considered therapeutic strategies to bypass PTCs is their "readthrough" based on small-molecule drugs. These molecules promote the incorporation of a near-cognate tRNA at the PTC position through the native polypeptide chain. In this review, we detailed the various existing strategies organized according to pharmacological molecule types through their different mechanisms. The positive results that followed readthrough molecule testing in multiple neuromuscular disorder models indicate the potential of this approach in peripheral neuropathies.
产生提前终止密码子(PTC)的无义突变可导致与野生型mRNA相比,突变mRNA加速降解,或产生截短的蛋白质。一种被认为绕过PTC的治疗策略是基于小分子药物的“通读”。这些分子通过天然多肽链促进近同源tRNA在PTC位置掺入。在这篇综述中,我们详细介绍了根据药理分子类型通过其不同机制组织的各种现有策略。在多个神经肌肉疾病模型中进行通读分子测试后得到的阳性结果表明了这种方法在外周神经病变中的潜力。